Cargando…

Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients

Detalles Bibliográficos
Autores principales: How, Joan, Gallagher, Kathleen M. E., Liu, Yiwen, Katsis, Katelin, Elder, Eva L., Larson, Rebecca C., Leick, Mark B., Neuberg, Donna, Maus, Marcela V., Hobbs, Gabriela S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873343/
https://www.ncbi.nlm.nih.gov/pubmed/35217807
http://dx.doi.org/10.1038/s41375-022-01533-0
_version_ 1784657444346003456
author How, Joan
Gallagher, Kathleen M. E.
Liu, Yiwen
Katsis, Katelin
Elder, Eva L.
Larson, Rebecca C.
Leick, Mark B.
Neuberg, Donna
Maus, Marcela V.
Hobbs, Gabriela S.
author_facet How, Joan
Gallagher, Kathleen M. E.
Liu, Yiwen
Katsis, Katelin
Elder, Eva L.
Larson, Rebecca C.
Leick, Mark B.
Neuberg, Donna
Maus, Marcela V.
Hobbs, Gabriela S.
author_sort How, Joan
collection PubMed
description
format Online
Article
Text
id pubmed-8873343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88733432022-02-25 Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients How, Joan Gallagher, Kathleen M. E. Liu, Yiwen Katsis, Katelin Elder, Eva L. Larson, Rebecca C. Leick, Mark B. Neuberg, Donna Maus, Marcela V. Hobbs, Gabriela S. Leukemia Letter Nature Publishing Group UK 2022-02-25 2022 /pmc/articles/PMC8873343/ /pubmed/35217807 http://dx.doi.org/10.1038/s41375-022-01533-0 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Letter
How, Joan
Gallagher, Kathleen M. E.
Liu, Yiwen
Katsis, Katelin
Elder, Eva L.
Larson, Rebecca C.
Leick, Mark B.
Neuberg, Donna
Maus, Marcela V.
Hobbs, Gabriela S.
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
title Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
title_full Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
title_fullStr Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
title_full_unstemmed Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
title_short Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
title_sort antibody and t-cell responses to sars-cov-2 vaccination in myeloproliferative neoplasm patients
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873343/
https://www.ncbi.nlm.nih.gov/pubmed/35217807
http://dx.doi.org/10.1038/s41375-022-01533-0
work_keys_str_mv AT howjoan antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT gallagherkathleenme antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT liuyiwen antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT katsiskatelin antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT eldereval antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT larsonrebeccac antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT leickmarkb antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT neubergdonna antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT mausmarcelav antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients
AT hobbsgabrielas antibodyandtcellresponsestosarscov2vaccinationinmyeloproliferativeneoplasmpatients